Ulrich Dauer
Director/Board Member chez Atriva Therapeutics GmbH
Fortune : 22 490 $ au 31/03/2024
Profil
Ulrich Dauer was the founder of 4SC AG, where he held the title of Chief Executive Officer from 1997 to 2013.
He is currently a Non-Executive Director at Atriva Therapeutics GmbH.
Dr. Dauer's former positions include Chief Executive Officer at OMEICOS Therapeutics GmbH and Ventaleon GmbH, and Chief Strategy Officer at Vectura GmbH.
He was also the Chief Executive & Financial Officer at Vivoryon Therapeutics NV from 2018 to 2021.
Dr. Dauer obtained a doctorate degree from Julius-Maximilians-Universität Würzburg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/12/2022 | 38 563 ( 0,15% ) | 22 490 $ | 31/03/2024 |
Postes actifs de Ulrich Dauer
| Sociétés | Poste | Début |
|---|---|---|
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Director/Board Member | - |
Anciens postes connus de Ulrich Dauer
| Sociétés | Poste | Fin |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Chief Executive Officer | 14/08/2023 |
| 4SC AG | Chief Executive Officer | 31/03/2013 |
Ventaleon GmbH
 Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Chief Executive Officer | - |
OMEICOS Therapeutics GmbH
 OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Chief Executive Officer | - |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Corporate Officer/Principal | - |
Formation de Ulrich Dauer
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| 4SC AG | Health Technology |
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Entreprise privées | 4 |
|---|---|
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Health Technology |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Health Technology |
